

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/68098 A3

(51) International Patent Classification⁷: **A61K 31/55.**
A61P 35/00

(21) International Application Number: **PCT/US01/08480**

(22) International Filing Date: **15 March 2001 (15.03.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/189,699 15 March 2000 (15.03.2000) US

(71) Applicant (for all designated States except US): **CHEM-
GENEX THERAPEUTICS, INC.** [US/US]; 34700 Cam-
pus Drive, Fremont, CA 94555 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BROWN, Dennis,
M.** [US/US]; 100 San Mateo Drive, Menlo Park, CA 94025
(US). **MICHAELS, Shawnya, J.** [US/US]; 206 Dolores
Street, El Granada, CA 94018 (US).

(74) Agents: **TRECARTIN, Richard, F.** et al.: Flehr Hohbach
Test Albritton & Herbert LLP, 4 Embarcadero Center, Suite
3400, San Francisco, CA 94111-4187 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(88) Date of publication of the international search report:
6 June 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **CEPHALOTAXINE ALKALOID COMBINATION COMPOSITIONS AND USES THEREOF**

(57) Abstract: A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a cephalotaxine and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl) butanedioate ester). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes.

WO 01/68098 A3

DORSEY & WHITNEY LLP

2002 JUN 17 AM 10:27

RECEIVED

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/08480

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/55 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBASE, EPO-Internal, CHEM ABS Data, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	C. VISANI ET AL: "Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on "in vitro" growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors" LEUKEMIA, vol. 11, 1997, pages 624-628, XP008000008 abstract --- -/--	1,3,6, 10-14

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

7 March 2002

Date of mailing of the international search report

22/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

Int. .tional Application No

PCT/US 01/08480

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBASE 'Online! ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; YUZHU Z. ET AL: "Homoharringtonine, cytarabine and aclarubicin (HAA) combination chemotherapy for acute myeloid leukemia (AML)." retrieved from STN Database accession no. 1998384948 XP002192356 abstract & CHINESE JOURNAL OF CLINICAL ONCOLOGY, (1998) 25/10 (758-759). ,</p>	1,3,6, 10-14
X	<p>--- DATABASE EMBASE 'Online! ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; LASTER JR. W.R. ET AL: "Therapeutic synergism (TS) of homoharringtonine (H) plus 5-fluorouracil (FU) against leukemia P388 (P388/O) and ARA-C-resistant P388 (P388/ARA-C)." retrieved from STN Database accession no. 82182588 XP002192357 abstract & PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, (1982) VOL. 23/- (NO. 786). CODEN: PAACA3,</p>	1,3,6, 10-14
X	<p>--- ZHANG ET AL: "Inhibitory effects of homoharringtonine and hydroxycamptothecin in combination with other agents on cancer cell growth" ASIA PACIFIC JOURNAL OF PHARMACOLOGY, SINGAPORE UNIVERSITY PRESS, SG, vol. 7, 1992, pages 191-195, XP002112006 ISSN: 0217-9687 page 194, right-hand column abstract</p>	1,3,6, 10-14
A	<p>--- TAKANO I ET AL: "Ester-type cephalotaxus alkaloids from cephalotaxus harringtonia var. drupacea" PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 44, no. 4, February 1997 (1997-02), pages 735-738, XP004292875 ISSN: 0031-9422 the whole document</p> <p>--- -/-</p>	1-14

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/08480

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TAKANO I ET AL: "NEW OXYGENATED CEPHALOTAXUS ALKALOIDS FROM CEPHALOTAXUS HARRINGTONIA VAR. DRUPACEA" JOURNAL OF NATURAL PRODUCTS, XX, XX, vol. 59, no. 12, December 1996 (1996-12), pages 1192-1195, XP000990654 ISSN: 0163-3864 abstract</p>	1-14

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)